Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adaptive Phage Therapeutics, Inc.
This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections of the hip or knee caused by at least 1 of the following organisms: Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus spp., Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, or Klebsiella pneumoniae.
This study will compare the safety and efficacy of DAIR procedure + Phage Therapy + Antibiotics versus DAIR procedure + Placebo + Antibiotics.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females ≥18 years of age
Recurrent PJI of the knee or hip
Female patients of childbearing potential who agree to use contraception.
Confirmed phage match
No anticipated need for long-term antibiotics
You may not be if
Soft tissue defect requiring reconstruction
Hardware misalignment
Additional orthopedic hardware in connection with the infected prosthesis
Active infection (other than PJI) requiring long term IV antibiotics
Unable to tolerate SAT
Septic shock or hemodynamic instability
Stage 4 or greater chronic kidney disease
Liver disease
Decompensated heart failure
Positive drug screen
Receiving chemotherapy
Immunocompromised
Treatment with antiviral medication within 2 weeks prior to randomization